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Campylobacter infection develop a self-controlled condition that does not require 7 antibiotics. Nevertheless, an antibiotic treatment is recommended when the 8 Campylobacter infection is severe or affects an immunocompromised host [3] . 9
Quinolones are a family of antimicrobials for the treatment of Campylobacter infections 10 in human and animals [1, 2] . However, the introduction of quinolones in veterinary 11 medicine has been reported to cause an emergence of quinolone-resistant 12 gift from Daiichi Sankyo Pharmaceutical, Co., Ltd. (Tokyo, Japan). Oligonucleotide 1 primers were synthesized by Life Technologies (Carlsbad, CA). A Ni-nitrolotriacetic 2 acid (Ni-NTA) protein purification kit was purchased from Life Technologies. 3 Restriction enzymes were obtained from New England BioLabs, Inc. (Ipswich, MA). 4
Supercoiled and relaxed pBR322 DNA were purchased from John Innes Enterprises 5 Ltd. (Norwich, United Kingdom). A protease inhibitor cocktail (Complete Mini, EDTA 6 free) was purchased from Roche Applied Science (Mannheim, Germany). 7
Bacterial strains and plasmids 8
Escherichia coli strain TOP-10 (Life Technologies Corp., Carlsbad, CA) was used as 9 the cloning host. The pUC118-HincII/BAP plasmid (Takara Bio, Kyoto, Japan) was 10 used to clone amplified DNA fragments. Escherichia coli strains BL-21 (DE3)/pLysS 11 (Merck KGaA, Darmstadt, Germany) were used for protein expression. Vector plasmid 12 pET-20b (+) (Merck KGaA) was used to construct expression plasmids for C. jejuni 13 proteins GyrA and GyrB. 14 DNA fragments encoding gyrA and gyrB were amplified by polymerase chain reaction 1 using the primers listed in Table 1 . The reaction mixture (25 µl) consisted of 2 primeSTAR GXL buffer (Mg 2+ plus); 200 µM each of dATP, dCTP, dGTP, and dTTP; 3 10 ng DNA from C. jejuni ATCC33560; 2.0 units of PrimeSTAR GXL DNA 4 polymerase (Takara Bio Inc., Kyoto, Japan); and 0.4 µM of each primer. PCR was 5 carried out in an iCycle Thermal Cycler (Bio-Rad Laboratories GmbH, California, US) 6 under the following amplification conditions: pre-denaturation at 98 ºC for 2 min, 35 7 cycles of denaturation at 98 ºC for 10 sec, annealing 50 ºC for 10 sec, extension 72 ºC 8 for 3 min, and a final extension step at 72 ºC for 2 min. The PCR products 9 corresponding to the 2.5-kb gyrA and 2.3-kb gyrB fragments were ligated into the 10 
DNA supercoiling assay and inhibition by quinolones 15
The DNA supercoiling activity of C. jejuni Figure 1C) . 18
ATP-dependent DNA supercoiling activities of WT DNA gyrase 19
GyrA and GyrB were examined for DNA supercoiling activity with relaxed pBR322 20 DNA as the substrate in the presence and absence of ATP ( Figure 1D 
Inhibition of DNA supercoiling by quinolones 4
The inhibitory effect of 10 quinolones on DNA gyrase was investigated by the 5 quinolone-inhibited DNA supercoiling assay. Each quinolone showed a dose-dependent 6 inhibition and their IC50s ranged from 0.4 (SIT) to 106.8 µg/mL (NAL), as summarized 7
in Table 2 . Two representative data are shown in Figure 1E , and the results for other 8 eight quinolones are presented in the supplementary figure. The MICs of 10 quinolones 9 ranged from 0.0078 to 4 µg/mL (Table 2) there is concern about the use of quinolones in animal production, as their use 16 selectively enriches quinolone-resistant Campylobacter, which can then be transmitted 17 to humans via the food chain [17]. Consequently, CIP-and ENR-resistant 18
Campylobacter strains are widely found in humans and animals, respectively. Hence, 19 the development of new quinolone-based antibiotics with higher activity than CIP and 20 ENR has become critical, as DNA gyrase, the target of quinolones, is an essential 21 enzyme required for bacterial growth in several strains. Efforts have been made to find 22 alternative quinolones for the treatment of C. jejuni infections. However, the 23 complicated culturing of C. jejuni has been a serious impediment for the study of this 24 pathogen, particularly the screening of new drugs. Studying the interaction of C. jejuni 1 DNA gyrase with quinolones is an important step to understand the quinolone structure-2 activity relationship and to select those quinolones with good antibacterial activity. 3
Based on findings of previous studies [14, 16] , His-tagged recombinant GyrA 4
and GyrB of C. jejuni were expressed and purified to obtain a functional DNA gyrase 5 after reconstitution. The reconstituted DNA gyrase allowed us to examine and compare 6 the inhibitory effect of ten quinolones. The inhibition of DNA supercoiling activities by 7 quinolone was observed in a dose-dependent manner, as previously found in other 8 bacterial DNA gyrase [18, 19, 20] . In the present study, eight quinolones (SIT, CIP, 9 LVX, SPX, GAT, MXF, ENR, and OFX) showed a high activity against C. jejuni DNA 10 gyrase, with IC50s of 0.4 to 2.3 µg/mL. In contrast, the remaining two quinolones, OXO 11 and NAL, showed a lower inhibitory activity, with IC50s of 15. 6 addition of a fluorine atom at position 6 was the earliest common modification in old 17 quinolones. This single alteration causes an increase in inhibitory activity of more than 18 10 fold against DNA gyrase and an improvement in MIC also up to 10 fold [24] . The 19 analysis of the quinolone structure-activity relationship showed that the other eight 20 quinolones shared an additional structural feature: a substituent that consisted of three 21 carbon atoms at R-1. Both of these structures exist in many quinolones. 22 In this study, SIT showed the highest inhibitory activity against C. jejuni DNA 23 gyrase with an IC50 of 0.4 µg/mL. Analysis of the quinolone structure-activity relationship showed that SIT has a fluorinate cyclopropyl ring at R-1 while other 1 fluoroquinolones have a cyclopropyl ring or a N1-C8 bridge. Furthermore, the addition 2 of a chloride substituent at R-8 may potentially provide an active compound. properties and accumulation in distinct quinolones [30] . As shown in These data suggested a stronger interaction of quinolones with C. jejuni and E. coli 4 DNA gyrase than with DNA gyrase from other bacteria. Moreover, the analysis of 5 QRDR sequences showed that E. coli has highly identical QRDR sequences to C. jejuni . 6 In E used in their study, 300 nM, comparing to our study (12.5 nM) might be the cause of the 2 discrepancy with our result (IC50 = 1.0 µg/mL). Further, the quality or specific activity 3 of the DNA gyrase used in our study might have been much higher than that used in 4 theirs. These data clearly exhibited the advantage of the usage of recombinant DNA 5 gyrase with high activity as produced in our study . 6 In conclusion, we have succeeded in producing and purifying C. jejuni DNA 7 gyrase, which is the sole target of quinolones. Based on the determination of the 8 inhibition activity of quinolones on recombinant C. jejuni DNA gyrase, we identified 9 SIT as a promising quinolone for the treatment of campylobacteriosis. The results of 10 this study suggested that the in vitro supercoiling inhibition assay may be a useful and 11 predictive technique to monitor the antibacterial potency of quinolones. 
